Alex Reyentovich, MD
Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1588723662
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,708 of the $49,437 with a category attached, or 68.2%. 31 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 44.5% of the total.
Across 239 payments — averaging $206.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$22K
- Pfizer$16K
- Akcea Therapeutics, Inc.$3K
- Medtronic$2K
- Abbott$2K
- Novartis$2K
- plus $3K from 25 others
Across 51 payments — averaging $3886.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$159K
- Ionis Pharmaceuticals, Inc.$34K
- Eidos Therapeutics, Inc.$5K
What the payments were for
- Consulting fees$33,70868%
- Speaking & faculty fees$7,05014%
- Travel & lodging$1,8404%
- Food & beverage$6,82314%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 25 | $21,988 |
| Pfizer | 30 | $15,810 |
| Akcea Therapeutics, Inc. | 1 | $2,650 |
| Medtronic(2 entities) | 4 | $2,407 |
| Abbott | 24 | $1,941 |
| Novartis | 48 | $1,669 |
| Transmedics, Inc. | 1 | $439 |
| Boehringer Ingelheim | 15 | $412 |
| AstraZeneca | 14 | $295 |
| Daiichi Sankyo Inc. | 12 | $248 |
| Merck | 11 | $236 |
| Bridgebio Pharma, Inc. | 5 | $235 |
| Johnson & Johnson | 9 | $183 |
| Actelion Pharmaceuticals US, Inc. | 10 | $159 |
| Bayer | 6 | $124 |
| Kestra Medical Technology Services, Inc. | 3 | $102 |
| Irhythm Technologies, Inc. | 2 | $80 |
| E.r. Squibb & Sons, L.L.C. | 2 | $58 |
| Amgen | 2 | $54 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| Impulse Dynamics (USA) Inc. | 2 | $40 |
| Ancora Heart, Inc. | 1 | $39 |
| Cvrx, Inc. | 1 | $36 |
| One Lambda, Inc. | 1 | $34 |
| Baxter Healthcare | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$15,439
- ONPATTRO$14,454
- AMVUTTRA$7,076
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,052
- CoreValve Evolut$850
- ENTRESTO$825
- ORGAN CARE SYSTEM$439
- CARDIOMEMS$303
- HeartWare HVAD$282
- MitraClip$140
- Mitra Clip system$135
- Attruby$125
How this compares
$49,437 in reported general payments places this provider in the 85th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 41 | $54,712 |
| EntrestoSacubitril/Valsartan | 28 | $40,222 |
| EliquisApixaban | 33 | $35,504 |
| Eplerenone | 46 | $2,785 |
| Metoprolol Succinate | 61 | $1,179 |
| Torsemide | 43 | $955 |
| Rosuvastatin Calcium | 32 | $565 |
| Atorvastatin Calcium | 38 | $231 |
| Furosemide | 33 | $153 |
| Amlodipine Besylate | 24 | $139 |
| Spironolactone | 20 | $120 |
| Losartan Potassium | 26 | $111 |
| Carvedilol | 12 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $412 | $54,71241 claims |
| NovartisEntresto | $1,669 | $40,22228 claims |
| PfizerEliquis | $15,810 | $35,50433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in New York
- Johanna ContrerasNew York$534K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
- Gabriel SayerNew York$95K
- Parag GoyalNew York$87K
- Paolo ColomboNew York$44K
- Melana YuzefpolskayaNew York$44K
- Kelly AxsomNew York$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.